Plasma Level of Transforming Growth Factor β1 Measured from the Azygos Vein Predicts Prognosis in Patients with Esophageal Cancer

Fukuchi, Minoru; Miyazaki, Tatsuya; Fukai, Yasuyuki; Nakajima, Masahiro; Sohda, Makoto; Masuda, Norihiro; Manda, Ryokuhei; Tsukada, Katsuhiko; Kato, Hiroyuki; Kuwano, Hiroyuki

doi:10.1158/1078-0432.ccr-1096-03

Cited by 35 publications

(22 citation statements)

References 22 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Concentration of serum TGF-β1 in total ESCC patients, oesophagectomy and palliation groups and control group are significantly higher in T4 than T1 + T2 primary tumours extension. These data are consistent with previous ones [21,22] demonstrating, that plasma TGF-β1 level in ESCC patients has been increasing along with the tumour progression. A similar relationship has been found between tissue TGF-β1 level and depth of tumour invasion in gastric and lung cancers [7,12,24].…”

Section: Discussionsupporting

confidence: 93%

“…Some studies have reported that there was no relationship between sTGF-β1 levels and disease progression [14,21]. However, in our study, serum levels of TGF-β1 tended to be higher in advanced oesophageal cancer than those in stage I and II.…”

Section: Discussioncontrasting

confidence: 81%

“…Some studies have reported that levels of TGF-β1 were significantly elevated in the serum or plasma of patients with liver [17], breast [18], lung [19,20], and oesophageal cancers [21,22]. In the present study we observed significantly higher sTGF-β1 levels in ESCC patients as compared to the controls.…”

Section: Discussionsupporting

confidence: 62%

See 2 more Smart Citations

Elevated levels of serum transforming growth factor-β 1 in oesophageal squamous cell carcinoma patients

Diakowska¹,

Lewandowski²,

Markocka−Mączka³

et al. 2011

View full text Add to dashboard Cite

Background: Transforming growth factor-β1 (TGF-β1) is a multifunctional cytokine involved in cancer development. The diagnostic significance of serum levels of transforming growth factor-β1 (sTGF-β1) in the oesophageal squamous cell carcinoma (ESCC) remains unclear. The aim of the study was to analyze sTGF-β1 concentrations in ESCC patients. The sTGF-β1 levels were assessed according to the clinical parameters in cancer patients. We determined sTGF-β1 concentrations in ESCC patients before and after oesophagectomy. The correlation between sTGF-β1 and serum levels of vascular endothelial growth factor (sVEGF-A) was examined as well. Material and methods: The study included 115 patients with ESCC and 57 healthy controls. Concentrations of sTGF-β1 were measured by ELISA tests and were compared with clinical parameters of cancer patients. Serum samples for sTGF-β1 evaluation 3 months after surgical resection were available in 41 cases. Results: Serum TGF-β1 level was significantly higher in ESCC compared to the control group (p < 0.001). Serum levels of TGF-β1 positively correlated with the depth of tumour invasion (p = 0.042). There were no differences in sTGF-β1 levels in patients stratified by the presence of regional and distant metastases and stage of cancer progression. The level of sTGF-β1 was significantly lower in ESCC patients after oesophagectomy than before surgical treatment (p = 0.002). A positive correlation between sTGF-β1 and sVEGF-A (p = 0.017) was observed. Conclusion: TGF-β1 seems to play an important role in tumour progression in ESCC. Further studies are needed to evaluate the utility of this cytokine as possible marker of ESCC.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussioncontrasting

confidence: 81%

See 1 more Smart Citation

Elevated levels of serum transforming growth factor-β 1 in oesophageal squamous cell carcinoma patients

Diakowska¹,

Lewandowski²,

Markocka−Mączka³

et al. 2011

View full text Add to dashboard Cite

show abstract

“…2A). The physiological concentration of 1 ng/ml TGFB1 (Fukuchi et al, 2004;Kiliç et al, 2009;Ouellete et al, 2005;Villar et al, 2009) seemed to be maximally effective for phosphorylation of SMAD2 and SMAD3. Time-course experiments revealed that both SMAD2 and SMAD3 were phosphorylated within 5 minutes following treatment with TGFB1 (1 ng/ml) (Fig.…”

Section: Tgfb1 Induces Phosphorylation Of Smad2 and Smad3 In Clendo Cmentioning

confidence: 98%

TGFB1 disrupts the angiogenic potential of microvascular endothelial cells of the corpus luteum

Maroni

Davis

2011

Journal of Cell Science

View full text Add to dashboard Cite

SummaryCyclical formation and regression of the ovarian corpus luteum is required for reproduction. During luteal regression, the microvasculature of the corpus luteum is extensively disrupted. Prostaglandin F2, a primary signal for luteal regression, induces the expression of transforming growth factor 1 (TGFB1) in the corpus luteum. This study determined the actions of TGFB1 on microvascular endothelial cells isolated from the bovine corpus luteum (CLENDO cells). We hypothesized that TGFB1 participates in the disruption of the microvasculature during luteal regression. TGFB1 activated the canonical SMAD signaling pathway in CLENDO cells. TGFB1 (1 ng/ml) significantly reduced both basal and fetal-calf-serum-stimulated DNA synthesis, without reducing cell viability. TGFB1 also significantly reduced CLENDO cell transwell migration and disrupted the formation of capillary-like structures when CLENDO cells were plated on Matrigel. By contrast, CLENDO cells plated on fibrillar collagen I gels did not form capillary-like structures and TGFB1 induced cell death. Additionally, TGFB1 caused loss of VE-cadherin from cellular junctions and loss of cellcell contacts, and increased the permeability of confluent CLENDO cell monolayers. These studies demonstrate that TGFB1 acts directly on CLENDO cells to limit endothelial cell function and suggest that TGFB1 might act in the disassembly of capillaries observed during luteal regression.

show abstract

“…This evidence was reinforced in a intraoperative study of the mean levels of TGF-1 from the azygos vein in patients with esophageal cancer, as higher levels significantly correlated with poorer survival. However, the majority of these cancers were esophageal squamous cell carcinoma, as opposed to adenocarcinoma (Fukuchi et al, 2004). The APC gene, a biomarker well known for its relationship with colon adenocarcinoma, has also been studied in esophageal carcinomas.…”

Section: Prognostic Value Of Biomarkersmentioning

confidence: 99%

Gastroesophageal Reflux Disease: Molecular Predictors in Neoplastic Progression of Barrett's Esophagus

François¹,

Khan²,

Yang³

et al. 2012

Gastroesophageal Reflux Disease

View full text Add to dashboard Cite

Plasma Level of Transforming Growth Factor β1 Measured from the Azygos Vein Predicts Prognosis in Patients with Esophageal Cancer

Cited by 35 publications

References 22 publications

Elevated levels of serum transforming growth factor-β 1 in oesophageal squamous cell carcinoma patients

Elevated levels of serum transforming growth factor-β 1 in oesophageal squamous cell carcinoma patients

TGFB1 disrupts the angiogenic potential of microvascular endothelial cells of the corpus luteum

Gastroesophageal Reflux Disease: Molecular Predictors in Neoplastic Progression of Barrett's Esophagus

Contact Info

Product

Resources

About